Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: Application to single-dose pharmacokinetic studies

Journal of Analytical Toxicology

Volumn 21, Issue 5, 1997, Pages 388-392

  Durol, Anna Liza B ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPNOTIC AGENT; IMIDAZOPYRIDINE DERIVATIVE; ZOLPIDEM;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; STANDARD;

EID: 0030768716     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/21.5.388     Document Type: Article

References (29)

1. H.D. Langtry and P. Benfield. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40: 291-313 (1990).
2. J.D. Hoehns and P.J. Perry. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin. Pharm. 12: 814-28 (1993).
3. J.J. Byrnes, D.J. Greenblatt, and L.G. Miller. Benzodiazepine receptor binding of nonbenzodiazpines in vivo: alpidem, zolpidem and zopiclone. Brain Res. Bull. 29: 905-908 (1992).
4. L. Schmid, M. Bottlaender, C. Fuseau, D. Fournier, E. Brouillet, and M. Mazière. Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor in vivo. J. Neurochem. 65: 1880-86 (1995).
5. D.J. Sanger, J. Benavides, G. Perrault, E. Morel, C. Cohen, D. Joly, and B. Zivkovic. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci. Biobehav. Rev. 18: 355-72 (1994).
6. P. Salvá and J. Costa. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin. Pharmacokinet. 29: 142-53 (1995).
7. A. Patat, S. Trocherie, J.J. Thebault, P. Rosenzweig, C. Dubruc, G. Bianchetti, L.A. Court, and P.L. Morselli. EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology 114: 138-46 (1994).
8. C.R. Rush and R.R. Griffiths. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharmacol. 16: 146-57 (1996).
9. S.M. Evans, F.R. Funderburk, and R.R. Griffiths. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J. Pharmacol. Exp. Ther. 255: 1246-54 (1990).
10. A. Patat, M.M. Naef, E. Van Gessel, A. Forster, C. Dubruc, and P. Rosenzweig. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin. Pharmacol. Ther. 56: 430-36 (1994).
11. N.J. Wesensten, T.J. Balkin, and G.L. Belenky. Effects of daytime administration of zolpidem versus triazolam on memory. Eur. J. Clin. Pharmacol. 48: 115-22 (1995).
12. T.J. Balkin, V.M. O'Donnell, N. Wesensten, U. McCann, and G. Belenky. Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 107: 83-88 (1992).
13. A. Richens, A.J. Mercer, D.M. Jones, A. Griffiths, and R.W. Marshall. Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo controlled study in healthy volunteers. Br. J. Clin. Pharmacol. 36: 61-65 (1993).
14. D.J. Greenblatt, J.S. Harmatz, C.E. Wright, L. Harrel, and R.I. Shader. Does zolpidem have unique clinical properties? - A pharmacodynamic comparison with triazolam and placebo. Clin. Pharmacol. Ther. 59: 179 (1996).
15. I. Berlin, D. Warot, T. Hergueta, P. Molinier, C. Bagot, and A.J. Puech. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J. Clin. Psychopharmacol. 13: 100-106 (1993).
16. T. Roehrs, L. Merlotti, F. Zorick, and T. Roth. Sedative, memory, and performance effects of hypnotics. Psychopharmacology 116: 130-34 (1994).
17. J.L. Jackson, J.W. Louwerens, F. Cnossen, and H.T.P. De Jong. Testing the effects of the imidazopyridine zolpidem on memory: an ecologically valid approach. Hum. Psychopharmacol. 7: 325-30 (1992).
18. M. Undén and B.R. Schechter. Next day effects after nighttime treatment with zolpidem: a review. Eur. Psychiatry 11(suppl 1): 21s-30s (1996).
19. P. Guinebault, C. Dubruc, P. Hermann, and J.P. Thénot. High-performance liquid chromatographic determination of zolpidem, a new sleep inducer, in biological fluids with fluorometric detection. J. Chromatogr. 383: 206-11 (1986).
20. G. Debailleul, F.A. Khalil, and P. Lheureux. HPLC quantification of zolpidem and prothipendyl in a voluntary intoxication. J. Anal. Toxicol. 15: 35-37 (1991).
21. D. Debruyne, J. Lacotte, B. Hurault de Ligny, and M. Moulin. Determination of zolpidem and zopiclone in serum by capillary column gas chromatography. J. Pharm. Sci. 80: 71-74 (1991).
22. V. Ascalone, L. Flaminio, P. Guinebault, J.P. Thénot, and P.L. Morselli. Determination of zolpidem, a new sleep-inducing agent, and its metabolites in biological fluids: pharmacokinetics, drug metabolism and overdosing investigations in humans. J. Chromatogr. 581: 237-50 (1992).
23. A. Tracqui, P. Kintz, and P. Mangin. High-performance liquid chromatographic assay with diode-array detection for toxicological screening of zopiclone, zolpidem, suriclone and alpidem in human plasma. J. Chromatogr. 616: 95-103 (1993).
24. Y. Gaillard, J.-P. Gay-Montchamp, and M. Ollagnier. Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection after solid-phase extraction. J. Chromatogr. 622: 197-208 (1993).
25. B. Ahrens, H. Schütz, H. Seno, and G. Weiler. Screening, identification and determination of the two new hypnotics zolpidem and zopiclone. Arzneimittel Forschung 44: 799-802 (1994).
26. F. Stanke, N. Jourdil, J. Bessard, and C. Bessard. Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. J. Chromatogr. B 675: 43-51 (1996).
27. D.J. Greenblatt, J.S. Harmatz, T.A. Gouthro, J. Locke, and R.I. Shader. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin. Pharmacol. Ther. 56: 100-11 (1994).
28. A. Durand, J.P. Thénot, G. Bianchetti, and P.L. Morselli. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev. 24: 239-266 (1992).
29. L. Pichard, G. Gillet, C. Bonfils, J. Domergue, J.-P. Thénot, and P. Maurel. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab. Dispos. 23: 1253-62 (1995).